1 The Efficacy and Safety of Pembrolizumab, Ipilimumab, and Nivolumab Monoteraphy

2 and Combination for Colorectal Cancer: A Systematic Review and Meta-Analysis

- 3 Albertus Ari Adrianto¹
- 4 Ignatius Riwanto¹
- 5 Udadi Sadhana²
- 6 Dewi Kartikawati Paramita^{3, 4, 5}
- 7 Henry Setyawan⁶
- 8 Kevin Christian Tjandra⁷
- 9 Danendra Rakha Putra Respati⁷
- 10 Derren David Christian Homenta Rampengan⁸
- 11 Roy Novri Ramadhan⁹
- 12 Gastin Gabriel Jangkang¹⁰
- 13 Endang Mahati¹¹
- ¹Department of Digestive Surgery, Faculty of Medicine, Universitas Diponegoro, Semarang,
 Indonesia
- ²Department of Anatomical Pathology, Faculty of Medicine, Universitas Diopnegoro,
 Semarang, Indonesia
- ³Department of Histology and Cell Biology, Faculty of Medicine, Public Health and Nursing,
- 19 Universitas Gadjah Mada, Yogyakarta, Indonesia
- ⁴Integrated Research Laboratory, Faculty of Medicine, Public Health and Nursing, Universitas
 Gadjah Mada, Yogyakarta, Indonesia;
- ⁵Study Center for Biotechnology, Universitas Gadjah Mada, Yogyakarta, Indonesia
- ⁶Department of Public Health, Faculty of Public Health, Universitas Diponegoro, Semarang,
 Indonesia;
- ⁷Department of Medicine, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia
- ⁸Medical Program, Faculty of Medicine, Universitas Sam Ratulangi
- ⁹Medical Program, Faculty of Medicine, Universitas Airlangga
- ¹⁰Medical Program, Faculty of Medicine, Universitas Lambung Mangkurat
- ¹¹Department of Pharmacology and Therapeutic, Faculty of Medicine, Diponegoro University,
- 30 Semarang, Indonesia
- 31 *Correspondence: Albertus Ari Adrianto
- 32 NOTE: Jhis Steprint reports new research that has not here pertilied by pae Seview and should not be used in goid of cligical practice.

33 Tel +628122824838

- 34 Fax -
- 35 Email: medpubdiponegoro@gmail.com
- 36 *Abstract*

37 **Background:** Colorectal cancer (CRC) ranks third globally in cancer-related mortality, with

- rising incidence, particularly in Asia, projecting a 60% surge by 2030. Metastatic CRC
- 39 (mCRC) presents a significant challenge with a grim 5-year survival rate of 14%. Emerging
- 40 evidence suggests that tumors with DNA mismatch repair deficiency (dMMR) and high
- 41 microsatellite instability (MSI-H) respond well to immune checkpoint inhibitors (ICIs),
- 42 marking a paradigm shift in therapeutic approaches. This systematic review and meta-
- 43 analysis aim to comprehensively assess Pembrolizumab, Nivolumab, and the combination of
- 44 Nivolumab and Ipilimumab in advanced CRC, considering their significant antitumor
- 45 *efficacy in MSI-H/dMMR mCRC.*

46 *Methods:* Following PRISMA guidelines and Cochrane Handbook standards, this study

47 covers 2014 to 2024, involving advanced CRC patients treated with ICIs. A comprehensive

48 literature search employed 12 independent authors across eight databases. Parameters such

49 as overall survival, progression-free survival, and objective response rate were extracted.

50 The Cochrane Collaboration's Risk of Bias version 2 tool assessed risk. Statistical analysis

51 *utilized mean difference and risk ratios with random-effect models due to anticipated*

52 heterogeneity. Robustness was ensured through publication bias analysis and sensitivity

53 *meta-analysis. Linear regression explored associations in subgroup analysis.*

54 *Results:* The meta-analysis evaluated ORR and OS across different immunotherapy

- 55 *interventions. Nivolumab, Nivolumab+Ipilimumab, and Pembrolizumab exhibited varying*
- 56 ORR and OS effect sizes with corresponding heterogeneity levels. Progression-free survival

(PFS) analysis also showed diverse effect sizes and heterogeneity levels across the three
interventions. The study provides a comprehensive overview of response rates and survival
outcomes for these immunotherapies in advanced CRC.

60 *Conclusions:* The study concludes that combination immunotherapy, particularly Nivolumab

61 *and Ipilimumab, presents a promising avenue for advanced CRC treatment, showing superior*

62 *efficacy. Pembrolizumab monotherapy also exhibited promise. While the study offers*

63 valuable insights, the identified heterogeneity emphasizes the need for additional research.

64 *Adverse effects were generally low, supporting the viability of the studied immunotherapies.*

65 *The study acknowledges limitations and calls for ongoing investigation to refine and validate*

66 these findings, marking a pioneering effort in systematically comparing short-term and long-

67 *term effects of anti-CTLA-4 and anti-PD-1 therapies in CRC.*

68 Keywords: Colorectal Cancer Immunotherapy, PD-1 and CTLA-4 Combination, Nivolumab,

69 Ipilimumab, Pembrolizumab Efficacy and Safety Profiles

70 Introduction

Colorectal cancer (CRC) ranks as the third most common cause of cancer-related mortality 71 72 globally[1]. Over the past thirty years, the incidence of CRC has surged in many nations, particularly in Asia, where a notable rise has been observed[2]. Projections indicate a 73 significant rise in its worldwide incidence, with an expected increase of 60% by the year 2030 74 [1,3]. The prognosis remains poor for individuals diagnosed with metastatic colorectal cancer 75 (mCRC), as evidenced by a 5-year survival rate of only 14%[4]. The incidence of CRC and its 76 77 associated mortality rate rise with advancing age, with a median age of diagnosis typically reported as 68 years old. A striking 93% of CRC-related deaths are observed in individuals 78

aged 50 years and older. The relative survival rates at 5 and 10 years post-diagnosis for CRC
stand at 65% and 58%, respectively[5].

81

Until recently, the treatment choices available for individuals with inoperable colorectal cancer 82 worldwide have been predominantly confined to chemotherapy and targeted therapies[6]. 83 Findings from several clinical trials indicate that CRC tumors identified by DNA mismatch 84 repair deficiency (dMMR) and a high level of microsatellite instability (MSI-H) exhibit 85 susceptibility to treatment with immune checkpoint inhibitors (ICIs)[7-9]. Tumors 86 87 characterized as MSI-H/dMMR possess an elevated tumor mutational burden, leading to the generation of neoantigens, thereby rendering MSI-H/dMMR tumors more immunogenic 88 compared to those with proficient DNA mismatch repair mechanisms. Consequently, MSI-89 90 H/dMMR tumors tend to harbor increased numbers of tumor-infiltrating lymphocytes, whose function can be potentiated by ICI therapy. Patients with MSI-H/dMMR mCRC typically 91 derive less benefit from standard chemotherapy compared to those with microsatellite 92 93 stable/mismatch repair-proficient mCRC[10,11]. However, MSI-H/dMMR status serves as a predictive indicator of favorable response to anti-programmed death (PD)-1 checkpoint 94 inhibitor therapy [8,12,13] 95

96

97 The interaction involving the PD-1 receptor and its ligands, PD-L1 and PD-L2, typically serves 98 as an immune checkpoint mechanism responsible for regulating the equilibrium between T-99 cell activation, immune tolerance, and preventing immune-related tissue damage. This pathway 100 is often exploited by tumors to evade immune surveillance[14]. PD-1 is present on T, B, and 101 natural killer T cells, as well as activated monocytes and a significant portion of tumor-102 infiltrating lymphocytes (TILs) in various malignancies[14]. When PD-L1 (found on cells of 103 diverse lineages) or PD-L2 (present on macrophages and dendritic cells) binds to the PD-1

receptor, it ultimately leads to the inhibition of T-cell function. Both PD-1 ligands have the 104 potential to be expressed either constitutively or induced in various cell types, which also 105 includes tumor cells[14]. Pembrolizumab is a selective humanized monoclonal antibody of the 106 immunoglobulin G4/ κ type, designed to specifically hinder the interaction between PD-1 and 107 PD-L1/PD-L2 by directly binding to PD-1[15]. Previous studies have shown that checkpoint 108 inhibitors targeting PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), 109 110 including nivolumab and ipilimumab, respectively, synergize and stimulate an immune response against tumors through separate but complementary mechanisms. Nivolumab, a 111 112 human monoclonal antibody blocking PD-1, has received accelerated approval from the U.S. Food and Drug Administration (FDA) for use either alone or in combination with low-dose 113 ipilimumab in patients diagnosed with MSI-H or dMMR mCRC. Another findings also 114 reported that both pembrolizumab and nivolumab, inhibitors targeting PD-1, have 115 demonstrated significant antitumor efficacy in patients with previously treated MSI-H/dMMR 116 metastatic CRC[7–9]. 117

118

Due to their distinct mechanism of action, immune checkpoint inhibitors are linked to adverse 119 events (AEs) that contrast with those typically associated with chemotherapy. These immune-120 related AEs commonly impact various bodily systems including the skin, gastrointestinal (GI) 121 122 tract, lungs, kidneys, endocrine glands, and liver. Timely detection and appropriate management of these AEs, which may involve the use of systemic corticosteroids as necessary, 123 could enhance outcomes for patients undergoing checkpoint inhibitor therapy (Brahmer et al., 124 2018). Understanding the predictors of response and resistance to immunotherapy is crucial for 125 identifying patients who are most likely to benefit from these agents. Pembrolizumab, 126 127 Nivolumab, and Ipilimumab represent novel therapeutic options for patients with advanced colorectal cancer, offering the potential for durable responses and improved survival outcomes. 128 129 Therefore, this systematic review and meta-analysis aims to provide a comprehensive overview

of the efficacy and safety profiles of Pembrolizumab, Nivolumab, and Ipilimumab in advanced
colorectal cancer, with insights into future directions and challenges in the immunotherapy
landscape.

133

134 Material and Method

135 <u>Registration</u>

The systematic review and meta-analysis titled "The Efficacy and Safety of Pembrolizumab,
Ipilimumab, and Nivolumab Monoteraphy and Combination for Advanced Colorectal Cancer:
A Systematic Review and Meta-Analysis" was officially registered on the Prospero on 24

139 February 2024 with registration number: CRD42024512511

140

141 *Eligibility criteria*

This review adhered to the guidelines stipulated by the Preferred Reporting Items for 142 Systematic Reviews and Meta-Analyses (PRISMA) statement and the Cochrane 143 Handbook[16,17]. The inclusion criteria encompassed studies involving patients of any age 144 diagnosed with advanced or metastatic colorectal cancer, regardless of microsatellite 145 146 instability-high and/or mismatch repair-deficient (MSI-H/ dMMR) status, treated by Pembrolizumab, Ipilimumab, and Nivolumab as the monotherapy or combination therapy. The 147 primary focus was assessing the efficacy and safety of this treatment. The criteria for inclusion 148 necessitated the availability of data on the mentioned primary outcomes published from 2014 149 until 2024. Furthermore, the eligible studies were restricted to observational designs 150 (cohort/case-control) or randomized clinical trials (RCTs) or clinical trial. 151

152

The exclusion criteria were technical reports, editor responses, narrative reviews, systematic reviews, meta-analyses, non-comparative research, in silico studies, in vitro studies, in vivo studies, scientific posters, study protocoals, and conference abstracts. For data synthesis, the study will be grouped based on relevant comparators that include the use of Nivolumab+Ipilimumab, Nivolumab, and Pembrolizumab monotherapy.

158

159 *Literature Search and Study Selection*

A comprehensive search of English literature across eight international databases— Scopus, 160 PubMed, Cochrane Library, Sage pub, ProQuest, Science Direct, Research Gate, 161 Epistemonikos—was conducted by a team of 12 independent authors from inception until 162 February 1st, 2024. To capture all potentially relevant literature, a combination of keywords 163 was utilized, employed the following keywords: "Pembrolizumab" or "Nivolumab" or 164 "Ipilimumab" and "colorectal carcinoma" and "therapeutic". The studies were organized and 165 managed using the Mendeley Group Reference Manager in the authors' library. Initially, 166 167 duplicate articles were removed, followed by screening based on titles and abstracts. Each researchers independently reviewed the titles and abstracts, resolving any disparities through 168 discussion until reaching an agreement. Subsequently, they collaborated in 6 pairs of group to 169 review the titles and abstracts of all retrieved articles. If necessary, the corresponding author 170 was involved to make the final decision. Articles that passed this initial screening underwent 171 full-text evaluation against predetermined inclusion/exclusion criteria. The full-text screening 172 was conducted by the same 12 independent researchers with any discrepancies resolved 173 through discussion with the corresponding author as the final decision maker. 174

175 **Table 1.** Keyword Used in Literature Searching

Database	Keywords
Scopus	"Pembrolizumab" or "Nivolumab" or "Ipilimumab" and "colorectal
PubMed	carcinoma" and "therapeutic"
Cochrane Library	
Sage pub	
ProQuest	
Science Direct	
Research Gate	
Epistemonikos	

176

177 *Data Extraction*

The following data were extracted for analytical purposes: study ID, publication year, country, 178 study design, sample size, baseline characteristics of participants (mean age and sex 179 distribution), follow-up duration, the number of participants in the buried and exposed K-wire 180 groups, and the outcomes of interest. These data, extracted by 12 independent authors, were 181 tabulated using Microsoft Excel 2019. The primary outcome assessment of efficacy 182 183 incorporated into two general parameters, survival and therapy response. The survival parameter is indicated as overall survival (OS), progression-free survival (PFS) (The duration 184 185 spanning both the treatment period and the subsequent phase following the intervention for a medical condition, such as cancer, wherein a patient sustains a state in which the disease neither 186 progresses nor deteriorates). Furthermore, the response evaluation was assessed by objective 187

response rate (ORR) These parameters were chosen to holistically evaluate the influence of the
therapeutic intervention among individuals afflicted with colorectal cancer. The adverse effect
occured during the treatment indicated as our secondary outcomes.

191

192 <u>Risk of Bias Assessment</u>

The evaluation of bias risk was carried out by five independent authors utilizing validated 193 instruments. To assess the quality of the included Randomized Controlled Trials (RCTs), the 194 Cochrane Collaboration's Risk of Bias version 2 (RoB v2) tool was employed, comprising 195 196 methodological assessments across five domains: (a) randomization process; (b) deviations from intended interventions; (c) missing outcome data; (d) measurement of the outcome; and 197 (e) selection of the reported results. The outcomes are depicted in Fig 2. The authors' appraisals 198 were categorized as "low risk," "high risk," or "some concerns" of bias. Two review authors 199 200 (KCT, DR) independently utilized the tool for each included study and documented supporting information for their assessments of risk of bias in each domain. In evaluating the quality of 201 included cohort/case-control studies or non randomized clinical trial, the Risk Of Bias In Non-202 randomised Studies - of Interventions (ROBINS-I) was utilized, covering seven domains: (1) 203 confounding; (2) selection of participants; (3) classification of intervention; (4) deviation from 204 intended intervention; (5) missing data; (6) measurement of outcomes; (7) selection of the 205 reported result. The authors' appraisals were categorized as "low risk," "high risk," or "some 206 207 concerns" of bias. Two review authors (KCT, DR) independently utilized the tool for each included study and documented supporting information for their assessments of risk of bias in 208 each domain. Any disparities in risk of bias assessments or justifications were addressed 209 through discussion to achieve consensus between the two review authors (KCT, DR) If needed, 210 corresponding author (EM) served as an arbiter to facilitate resolution 211

212

213 <u>Statistical Analysis</u>

For the analytical synthesis of continuous variable outcomes, we employed the mean difference 214 (SMD) with 95% confidence intervals (95% CI), utilizing the Inverse-Variance formula. 215 Dichotomous variable outcomes were pooled into risk ratios (RR) with 95% CI using the 216 Mantel-Haenszel formula. Given the anticipated substantial heterogeneity due to variations in 217 population characteristics and follow-up durations, random-effect models were selected for this 218 219 review. Heterogeneity between studies was assessed using the I-squared (I2) statistic, where values exceeding 50% were categorized as significant heterogeneity. To facilitate pooled 220 221 analysis, we employed a combined formula from Luo D et al.[15] and Wan X et al.[16] for transforming data expressed as the median and interquartile range (IQR), or median, minimum, 222 and maximum into mean and standard deviations (SD). 223

224 <u>Reporting bias and Certainity assessment</u>

Publication bias analysis was conducted when there were more than 10 studies for each outcome of interest. In cases of funnel plot asymmetry, a thorough examination of characteristics aimed to discern whether observed asymmetry could be attributed to publication bias or other factors like methodological heterogeneity among studies. All statistical analyses were executed using JAMOVI 2.3. The robustness of outcomes was scrutinized through sensitivity meta-analysis, exclusively considering studies with an overall low risk of bias.

231

In the subgroup analysis, a commonly employed statistical methodology for data analysis involves elucidating associations between a dependent variable and one or more independent variables. Utilizing linear regression, the model centers on the dependent variable (e.g., sample size, age, sex, and follow-up duration), evaluating whether these variables influence the observed associations. The selection of variables is guided by theoretical considerations and their relevance to analytical objectives. JAMOVI 2.3 was employed for conducting subgroupanalysis, ensuring robust data interpretation.

239 **Result**

240 <u>Study Selection and Characteristics</u>

A comprehensive literature search across eight international databases identified a total of 241 27,974 studies. Then the filter of released date and type of article were performed, 15,955 242 articles were automatically removed before being included into screening process. After the 243 244 elimination of duplicate entries and initial screening based on titles and abstracts, 11,519 studies were removed due to irrelevant topics and 458 studies were removed due to non-RCT 245 and non-clinical trial studies, resulting in a final selection of 42 studies. Subsequently, a 246 247 thorough evaluation of these 42 studies in full-text format revealed that 24 studies did not meet the desired outcomes and 5 studies were not retrievable. Consequently, only 13 studies satisfied 248 the eligibility criteria and were included in the final analysis, as illustrated in Figure 1. Sample 249 sizes ranged from 11 to 307, with follow-up durations varying from 5.3 month to 44.5 month. 250 A comprehensive overview of the baseline characteristics of the included studies is presented 251 in Table 2. 252

253

254

255

Table 2. Study Characteristic

No	Title	Author	Country	Study	Population									
•		;Year	/Place	Desig n	Sample size (n)	Mal e (n)	Femal e (n)	Age (years)	Interve n-tion	Con t-rol	Interve n-tion (n)	Cont- rol (n)	Follow- up	Dosage
1	Safety of Nivolumab plus Low- Dose Ipilimumab in Previously Treated Microsatelli te Instability- High/Mism atch Repair- Deficient Metastatic Colorectal Cancer[18]	Morse, et al; 2019	USA	Cohor t	119	Nr	Nr	Nr	Nivolu m-ab + Ipilimu mab	Nill	119	Nill	13.4 months	Nivolumab 3 mg/kg plus 1 mg/kg ipilimumab Q3W followed by nivolumab 3 mg/kg Q2W
2	Safety and antitumor activity of the anti– PD-1 antibody pembrolizu mab in	O'Neil, et al; 2017	Canada, France, Italy, the Republic of Korea, Spain, the	Cohor t	23	13	10	57 (40– 78)	Pembro l- izumab	Nill	23	Nill	5.3 months	10 mg/kg

	patients with advanced colorectal carcinoma[1 9]		United Kingdo m, and the United States											
3	Safety and antitumor activity of the anti-PD- 1 antibody pembrolizu mab in patients with recurrent carcinoma of the anal canal[20]	Ott, et al; 2017	Europe and the USA	Cohor t	25	2	23	63 (46– 82	Pembro 1- izumab	Nill	25	Nill	10.6 months	10 mg/kg
4	RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with	Cohen, et al; 2020	Nr	Non- rando mized Clinic al Trial	57	30	27	56.5 (45.8– 63.8)	Nivolu m-ab + Ipilimu m-ab	Nill	57	Nill	18.1 months	3 mg/kg intravenously and ipilimumab 1 mg/kg intravenously

	microsatellit e instability- high/mismat ch repair- -deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study[21]													
5	Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)[22]	Okuma , et al; 2023	Japan	Non- rando mized Clinic al Trial	11	3	8	70 (54– 78)	Nivolu m-ab	Nill	11		24.7 months	240 mg/kg
6	Pembrolizu mab versus chemothera	Diaz, et al; 2022	Japan	Rand omize d	307	153	154	62.5 (24– 93)	Pembro l- izumab	che mot	153	154	44.5 months	200 mg/kg

	py for			Clinic						hera				
	microsatellit													
				al						ру				
	e			Trial										
	instability-													
	high or													
	mismatch													
	repair-													
	deficient													
	metastatic													
	colorectal													
	cancer													
	(KEYNOTE													
	-177): final													
	analysis of a													
	randomised,													
	open-label,													
	phase 3													
	study[23]													
7	Pembrolizu	André,	USA	Rand	307	153	154	63.0	Pembro	che	153	154	32.4	200 mg/kg
	mab in	et al;		omize				(24–	1-	mot			months	
	Microsatelli	2020		d				93)	izumab	hera				
	te-			Clinic						py				
	Instability–			al						PJ				
	High			Trial										
	Advanced			11101										
	Colorectal													
	Concer[24]													
8	Pembrolizu	Yoshin	Japan,	Rand	48	23	25	64 (24–	Pembro	che	22	26	45.3	200 mg/kg
0	mab in	o, et al;	Korea,	omize	-10	25	25	83)	1-	mot		20	(range	200 mg/kg
	Asian	0, et al, 2022		d					izumab	hera			38.1–	
			Singapor	u Clinic					IZUIIIAU				57.8)	
	patients with		e, and Taiwan							ру				
	with		Taiwan										months	

	microsatellit e- instability- high/mismat ch-repair- deficient colorectal cancer[24]			al Trial										
9	PD-1 Blockade in Tumors with Mismatch- Repair Deficiency[7]	Le, et al; 2015	Nr	Cohor t	41	24	17	46 (24– 65)	Pembro l- izumab	Nill	41	Nill	36 weeks	10 mg/kg
10	Nivolumab in patients with metastatic DNA mismatch repair deficient/mi crosatellite instability- high colorectal cancer (CheckMate 142): results of an open-	Overm an, et al; 2017	8 countries	Non- rando mized Clinic al Trial	74	44	30	52·5 (44·0– 64·0)	Nivolu m-ab	Nill	74	Nill	12·0 months	3 mg/kg

	label, multicentre, phase 2 study[8]													
11	Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study[25]	Morris, et al; 2017	USA	Non- rando mized Clinic al Trial	37	10	27	56 (51– 64)	Nivolu m-ab	Nill	37	Nill	10.1 months	3 mg/kg
12	First-Line Nivolumab Plus Low- Dose Ipilimumab for Microsatelli te Instability- High/ Mismatch Repair- Deficient	Lenz, et al; 2021	6 countries	Cohor t	45	23	22	66 (21- 85)	Nivolu m-ab + Ipilimu m-ab	Nill	45	Nill	24.2 months	Nivolumab 3 mg/kg and low- dose ipilimumab 1 mg/kg

	Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study[26]													
13		Overm an, et al; 2018	USA	Cohor t	119	70	49	58 (21- 88)	Nivolu m-ab + Ipilimu m-ab	Nill	119	Nill	13.4 months	Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg

Figure 1. PRISMA 2020 flow diagram.

259 <u>Risk of Bias in Studies</u>

- 260 Each clinical trial and randomized controlled trial underwent a rigorous evaluation employing
- the ROB-2 method. Among the identified studies, three exhibited a level of bias concern,
- primarily attributed to confounding, classification of interventions, missing data, and reported
- results. The visualization of the risk-of-bias assessment is presented in Figure 2.
- Figure 2. (A) ROBINS-I Risk of Bias Assessment; (B) ROB-2 Risk of Bias Assessment
- 265 *Objective response rate (ORR)*
- 266 Three studies that administered Nivolumab reported ORR with an effect size of 0.34 [95% CI

0.18; -0.49, P<0.001]. Heterogeneity was found to be moderate and the funnel plot shows no
evidence of heterogeneity.

- Figure 3. (A) Forest plot of ORR nivolumab intervention; (B) Funnel plot of ORR nivolumabintervention
- 271 Four studies that administered Nivolumab and Ipilimumab reported ORR with an effect size of
- 272 **0.53** [95% CI 0.42; -0.65, P<0.001]. Heterogeneity was found to be high and the funnel plot
- shows evidence true of heterogeneity.
- **Figure 4.** (A) Forest plot of ORR Nivolumab and Ipilimumab intervention; (B) Funnel plot of
- 275 ORR Nivolumab and Ipilimumab intervention

276

Six studies that administered Pembrolizumab reported ORR with an effect size of 0.34 [95%
CI 0.19; 0.48, P<0.001]. Heterogeneity was found to be high and the funnel plot shows
evidence true of heterogeneity.

- **Figure 5.** (A) Forest plot of ORR Pembrolizumab intervention; (B) Funnel plot of ORR
- 281 Pembrolizumab intervention

282

283 <u>Overall Survival</u>

Three studies that administered Nivolumab reported OS with an effect size of **0.68** [95% CI **0.52**; **0.84**, P<**0.001**]. Heterogeneity was found to be moderate and the funnel plot shows no evidence true of heterogeneity.

Figure 6. (A) Forest plot of OS Nivolumab intervention; (B) Funnel plot of OS Nivolumab

288 intervention

Four studies that administered Nivolumab and Ipilimumab reported OS with an effect size of **0.84 [95% CI 0.81; 0.88, P<0.001]**. Heterogeneity was found to be absent and the funnel

- 291 plot shows no evidence true of heterogeneity.
- 292

Figure 7. (A) Forest plot of OS Nivolumab and Ipilimumab intervention; (B) Funnel plot of

294 OS nivolumab and Ipilimumab intervention

Five studies that administered Pembrolizumab reported OS with an effect size of **0.56** [95%

CI 0.37; 0.75, P<0.001]. Heterogeneity was found to be high and the funnel plot shows
 evidence true of heterogeneity.

298

- 299 Figure 8. (A) Forest plot of OS Pembrolizumab intervention; (B) Funnel plot of OS
- 300 Pembrolizumab intervention

301

302 <u>Progression-free survival (PFS)</u>

303	Three studies that administered Nivolumab reported PFS with an effect size of 0.53 [95% CI
304	0.43; 0.64, P<0.001]. Heterogeneity was found to be low and the funnel plot shows no evidence
305	true of heterogeneity
306	
307	Figure 9. (A) Forest plot of PFS Nivolumab intervention; (B) Funnel plot of PFS Nivolumab
308	intervention
309 310 311	Four studies that administered Nivolumab and Ipilimumab reported PFS with an effect size of 0.72 [95% CI 0.67; 0.77, P<0.001] . Heterogeneity was found to be absent and the funnel plot shows no evidence true of heterogeneity.
312	
313	Figure 10. (A) Forest plot of OS Nivolumab and Ipilimumab intervention; (B) Funnel plot of
314	OS Nivolumab and Ipilimumab intervention
315	
316 317 318	Five studies that administered Pembrolizumab reported PFS with an effect size of 0.53 [95% CI 0.34; 0.72, P<0.001]. Heterogeneity was found to be high and the funnel plot shows evidence true of heterogeneity.
319	
320	Figure 11. (A) Forest plot of PFS Pembrolizumab intervention; (B) Funnel plot of PFS
321	Pembrolizumab intervention
322	The effect size of each subgroup is summarized in Table 3 below.
323	Table 3. Size effects comparison of each subgroup
324	Objective Response Rate (ORR)

Intervention	Effect Size (95% CI)
Nivolumab	0.34 (0.18; -0.49)
Nivolumab + Ipilimumab	0.53 (0.42; -0.65)
Pembrolizumab	0.34 (0.19; 0.48)

325 **Overall Survival (OS)**

Intervention	Effect Size (95% CI)
Nivolumab	0.68 (0.52; 0.84)
Nivolumab + Ipilimumab	0.84 (0.81; 0.88)
Pembrolizumab	0.56 (0.37; 0.75)

326 **Progression-Free Survival (PFS)**

Intervention	Effect Size (95% CI)
Nivolumab	0.53 (0.43; 0.64)
Nivolumab + Ipilimumab	0.72 (0.67; 0.77)
Pembrolizumab	0.53 (0.34; 0.72)

327 Discussion

Immunotherapy stands as a pivotal cornerstone in tumor control, and the exploration of combination immunotherapy involving multiple agents has emerged as a promising strategy. This comprehensive approach strategically intervenes in diverse immune response processes, encompassing chemoradiotherapy, targeted therapy, and interactions with immune pathways. By orchestrating a multifaceted anti-tumor immune response, combination immunotherapy seeks to mitigate the risk of drug resistance, marking it as a highly promising avenue for investigation[28].

Among the various combinations being studied, the concurrent administration of anti-PD-1 (nivolumab and ipilimumab) and anti-CTLA-4 (ipilimumab) has exhibited notable efficacy in tumor treatment[29,30]. This combination has demonstrated positive outcomes and substantial improvements in patients with metastatic melanoma, advanced renal cell carcinoma (RCC), and metastatic colorectal cancer (CRC)[30]. Cope et al. reported superior response rates in recurrent small cell lung cancer (SCLC) when treated with nivolumab plus ipilimumab, surpassing conventional chemotherapy and suggesting potential long-term survival

benefits[31]. Additionally, Ready et al. provided evidence supporting the effectiveness and
tolerability of the combination of nivolumab and low-dose ipilimumab as a first-line treatment
for advanced/metastatic non-small cell lung cancer (NSCLC)[32].

In the realm of combination immunotherapy, the inclusion of pembrolizumab has further 345 broadened the horizon of treatment modalities. Pembrolizumab, an anti-PD-1 agent, has 346 demonstrated its efficacy in various malignancies[33,34]. The concurrent use of 347 pembrolizumab with nivolumab and ipilimumab has shown promising outcomes, particularly 348 in advanced RCC. Shao's conditional survival analysis of first-line treatment highlighted that 349 patients with advanced RCC undergoing pembrolizumab in combination with nivolumab and 350 ipilimumab therapy exhibited a high survival rate compared to those receiving sunitinib[35]. 351 This accumulating evidence underscores the potential synergistic effects of combining 352 immunotherapeutic agents, notably anti-PD-1 and anti-CTLA-4, in conjunction with 353 pembrolizumab, opening new avenues for the advancement of cancer treatment modalities. 354

355

The primary objective of this investigation was to assess the effectiveness and safety of immunotherapy drugs in the context of colorectal cancer. A comprehensive analysis was conducted, incorporating data from a total of 13 studies, encompassing a sample size of 1337 patients. The assessment of Efficacy (ORR, OS, PFS) for each groups with the investigation of adverse events and survival can validate the safety of this immunotherapy. However, AEs will only be covered descriptively in this study due to the different ways in which they have been presented in previous studies.

363

The combination of nivolumab and ipilimumab demonstrates the highest efficacy, with an ORR of 0.53, OS of 0.84, and PFS of 0.72. Pembrolizumab monotherapy also shows promising results, with an ORR of 0.34, OS of 0.56, and PFS of 0.53. However, the heterogeneity observed in some of the outcomes highlights the need for further studies to confirm these findings.

The combination of nivolumab and ipilimumab has been shown to be effective in various cancers, including colorectal carcinoma. The combination of these two medicine may enhance the immune response against cancer cells by targeting different checkpoints in the immune system. The high efficacy observed in our meta-analysis supports the use of this combination in mCRC patients[18].

Pembrolizumab, a PD-1 inhibitor, has been approved for the treatment of mCRC patients with dMMR or MSI-H tumors. The promising results observed in our meta-analysis suggest that pembrolizumab may be a viable treatment option for a broader range of mCRC patients. Further research is needed to confirm these findings and to explore the optimal treatment strategies for mCRC patients[19].

Ipilimumab+Nivolumab and Nivolumab monotherapy have been evaluated in earlier meta-379 analyses conducted across multiple publications with varying cancer types. It has been reported 380 that the combination outperforms nivolumab monotherapy in terms of ORR and DCR, however 381 patients may experience increased AEs[36]. One particular instance where using 382 Ipilimumab+Nivolumab has been clearly demonstrated in multiple meta-analyses to result in 383 384 improved ORR response[37–39]. Ipilimumab+Nivolumab use, however, still requires cautious consideration because of the possibility of excessive adverse effects. Therefore, more thorough 385 research is required to determine how each type of cancer is affected by the combination of 386 387 Ipilimumab and Nivolumab[40].

The Adverse Effects (AEs) found accoding to previous meta-analyses indicating a high 388 incidence of AEs in the gastrointestinal system. However, in contrast, with the endocrine 389 system, the use of anti-CTLA-4 or anti-PD-1 immunotherapy is reported to have a greater 390 potential to cause endocrine issues (such as hypothyroidism, hyperthyroidism, thyroiditis, and 391 adrenal insufficiency) in other cancers[41,42]. These findings are also in line with the study 392 conducted by Almutairi AR, et al., 2020, who stated that Healthcare providers must remain 393 vigilant in monitoring for immune-related adverse events (irAEs) subsequent to combined 394 therapeutic interventions[43]. 395

Additionally, particular attention should be directed towards gastrointestinal and cutaneous 396 irAEs in the context of ipilimumab therapy. Furthermore, clinicians should be cognizant of the 397 398 potential occurrence of irAEs associated with hyperglycemia, thyroid dysfunction, hepatic abnormalities, and musculoskeletal disorders following administration of nivolumab and 399 400 pembrolizumab[43]. However, this treatment strategy is still preferable compared to 401 conventional chemotherapy since it has better efficacy with the same adverse effects as stated by O'bryne K, et al., 2023, There was no statistically significant difference in the occurrence 402 of adverse events (AEs) necessitating discontinuation between the combination of nivolumab 403 404 and ipilimumab (NIVO + IPI) and pembrolizumab combined with chemotherapy, as well as between NIVO + IPI and pembrolizumab monotherapy. However, it is noteworthy that the 405 incidence of treatment-related grade ≥ 3 AEs was higher with NIVO + IPI compared to 406 pembrolizumab monotherapy[39]. 407

408 <u>Strength and limitation</u>

To our knowledge, this study represents the first systematic review and meta-analysis that compares both short-term and long-term effects of presently available anti-CTLA-4 and anti-PD-1 combination or monotherapies for treating patients with CRC. The PICOS criteria

necessitated significant follow-up period in each trial to mitigate potential bias arising from 412 heavily censored data in the tails of treatment arms during the observation period. 413 Methodologically, the analysis was executed utilizing the meta library package in the Jamovi 414 for the comprehensive analysis. The metabias package facilitated the execution of the Egger 415 test, revealing evidence of heterogeneity for ORR, OS, and PFS outcomes. Additionally, the 416 funnel plots also indicated evidence of heterogeneity for these outcomes. However, it is 417 noteworthy that the prevalence of AEs, in general, remained at a low level, with instances of 418 either absent or non-significant heterogeneity for certain AEs. 419

However, this study does have some limitations. Due to variations in the presentation of 420 adverse events (AEs) across studies, with one individual potentially experiencing two or more 421 422 AEs simultaneously, extracting data posed challenges for us. Additionally, It can be quite challenging to classify an AE as a potential immune-related AE (irAE), as this determination 423 may vary among trials or observers. This variability could introduce detection bias, particularly 424 425 because our analysis included both open-label and double-blind trials. Such variations might result in an overestimation of the incidence of potential irAEs. Nevertheless, we made efforts 426 to mitigate this by only including patients treated with either anti-CTLA-4 or anti-PD-1 427 428 monotherapies or combination therapies, thereby excluding AEs that could be attributed to other treatments or immunotherapies. Furthermore, we employed the random-effects model for 429 the meta-analyses and conducted subgroup analyses to address high heterogeneity, aiming to 430 accommodate potential variations in the outcomes observed across the included studies. 431 Moreover, significant statistical heterogeneity observed in most analyses is a crucial 432 consideration. Variations in study designs, tumor stage, prior treatment history, and other 433 characteristic among the included studies could have contributed to this heterogeneity. 434

435 Conclusion

In conclusion, the exploration of combination immunotherapy involving anti-PD-1 and anti-CTLA-4 agents presents a promising avenue in cancer treatment, demonstrating notable efficacy across various cancers, including colorectal cancer (CRC). The concurrent use of nivolumab and ipilimumab, particularly, showcased superior efficacy in terms of objective response rate (ORR), overall survival (OS), and progression-free survival (PFS). Pembrolizumab monotherapy also exhibited promising results, highlighting its efficacy in treating CRC.

While the study, encompassing 13 studies with 1337 patients, provides valuable insights into 443 the effectiveness and safety of immunotherapy in CRC, the identified heterogeneity in some 444 outcomes emphasizes the necessity for additional research and exploration. Adverse effects, 445 mainly observed in the gastrointestinal and endocrine systems, were generally low in incidence. 446 Despite the higher incidence of treatment-related grade ≥ 3 adverse events with the nivolumab 447 and ipilimumab combination, the superior efficacy observed supports its consideration as a 448 449 viable treatment option. This study represents a pioneering systematic review comparing shortterm and long-term effects of anti-CTLA-4 and anti-PD-1 therapies in CRC, acknowledging 450 certain limitations and the need for ongoing investigation to refine and validate these findings. 451

452

453

454 Data availability

455 Underlying data

456 All data underlying the results are available as part of the article and no additional source457 data are required.

458 *Reporting guidelines*

459	Mendeley Data doi: 10.17632/zhvz39sggy.1.
460	Data are available under the terms of the Creative Commons Attribution 4.0 International
461	license (CC-BY 4.0).
462	
463	Funding
464	The author(s) declared no funding information available.
465	
466	Competing interests
467	No competing interests were disclosed.
468	
469	Grant information
470	The author(s) declared that no grants were involved in supporting this work.
471	
472	Acknowledgment

We would like to express our sincere gratitude to the Indonesian Health Research Foundation 473 for their invaluable contribution in reviewing and enhancing the quality of this systematic 474 review and meta-analysis. Their expertise and insightful feedback have significantly enriched 475 the rigor and comprehensiveness of our research. We acknowledge the Foundation's 476 477 commitment to advancing healthcare research and their dedication to fostering excellence in scientific inquiry. This collaboration has been instrumental in shaping the robustness of our 478 study, and we extend our heartfelt appreciation for their support in promoting the advancement 479 480 of health knowledge.

482 **Reference**

- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global
 Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide
 for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209–49.
- 2. Safiri S, Sepanlou SG, Ikuta KS, Bisignano C, Salimzadeh H, Delavari A, et al. The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019 Dec 1;4(12):913–33.
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer
 incidence and mortality worldwide: Sources, methods and major patterns in
 GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359–86.
- 493 4. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal
 494 cancer statistics, 2017. CA Cancer J Clin. 2017 May 6;67(3):177–93.
- 495 5. American Cancer Society. Colorectal Cancer Screening* Prevalence (%) among Adults
 496 Age 50 Years and Older by State, 2012. 2014.
- 497 6. Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, et al. Pan498 Asian adapted ESMO consensus guidelines for the management of patients with
 499 metastatic colorectal cancer: A JSMO-ESMO initiative endorsed by CSCO, KACO,
 500 MOS, SSO and TOS. Annals of Oncology. 2018 Jan 1;29(1):44–70.
- 501 7. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade
 502 in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine. 2015
 503 Jun 25;372(26):2509–20.
- 8. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017 Sep 1;18(9):1182–91.
- 508 9. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair
 509 deficiency predicts response of solid tumors to PD-1 blockade. Science (1979). 2017 Jul
 510 28;357(6349):409–13.
- Heinemann V KNBH et al. Somatic DNA mutations, tumor mutational burden (TMB),
 and MSI status: Association with efficacy in patients (pts) with metastatic colorectal
 cancer (mCRC) of FIRE-3 (AIO KRK-0306). J Clin Oncol . 2018;36:3591a.
- Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, et al.
 Mismatch repair status and BRAF mutation status in metastatic colorectal cancer
 patients: A pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.
 Clinical Cancer Research. 2014 Oct 15;20(20):5322–30.
- 518 12. Diaz LA MADJ et al. Pembrolizumab therapy for microsatellite instability high (MSI-H)
 519 colorectal cancer (CRC) and non-CRC. J Clin Oncol . 2017;35:3071a.

Marginean EC, Melosky B. Is there a role for programmed death ligand-1 testing and
immunotherapy in colorectal cancer with microsatellite instability?: Part II-the
challenge of programmed death ligand-1 testing and its role in microsatellite instabilityhigh colorectal cancer. In: Archives of Pathology and Laboratory Medicine. College of
American Pathologists; 2018. p. 26–34.

- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Vol. 12,
 Nature Reviews Cancer. 2012. p. 252–64.
- 527 15. O'Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, et al. Safety
 528 and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with
 529 advanced colorectal carcinoma. PLoS One. 2017 Dec 1;12(12).
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
 PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Vol.
 372, The BMJ. BMJ Publishing Group; 2021.
- 533 17. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated
 534 guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for
 535 Systematic Reviews of Interventions. Vol. 10, The Cochrane database of systematic
 536 reviews. NLM (Medline); 2019. p. ED000142.
- 18. Morse MA, Overman MJ, Hartman L, Khoukaz T, Brutcher E, Lenz HJ, et al. Safety of
 Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite InstabilityHigh/Mismatch Repair-Deficient Metastatic Colorectal Cancer. Oncologist. 2019 Nov
 1;24(11):1453–61.
- 541 19. O'Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, et al. Safety
 542 and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with
 543 advanced colorectal carcinoma. PLoS One. 2017 Dec 1;12(12).
- Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, et
 al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients
 with recurrent carcinoma of the anal canal. Ann Oncol. 2017 May 1;28(5):1036–41.
- 547 21. Cohen R, Bennouna J, Meurisse A, Tournigand C, De La Fouchardière C, Tougeron D,
 548 et al. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in
 549 patients with microsatellite instability-high/mismatch repair-deficient metastatic
 550 colorectal cancer: The GERCOR NIPICOL phase II study. J Immunother Cancer. 2020
 551 Nov 3;8(2).
- 552 22. Okuma HS, Watanabe K, Tsuchihashi K, Machida R, Sadachi R, Hirakawa A, et al.
 553 Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and
 554 Relation with Immune Phenotypic Analysis (the ROCK Trial). Clinical Cancer
 555 Research. 2023 Dec 15;29(24):5079–86.
- Diaz LA, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab
 versus chemotherapy for microsatellite instability-high or mismatch repair-deficient
 metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, openlabel, phase 3 study. Lancet Oncol. 2022 May 1;23(5):659–70.

- Yoshino T, Andre T, Kim TW, Yong WP, Shiu KK, Jensen BV, et al. Pembrolizumab
 in Asian patients with microsatellite-instability-high/mismatch-repair-deficient
 colorectal cancer. Cancer Sci. 2023 Mar 1;114(3):1026–36.
- Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, et al. Nivolumab for
 previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, singlearm, phase 2 study. Lancet Oncol. 2017 Apr 1;18(4):446–53.
- Lenz HJ, Eric ;, Cutsem V, Limon ML, Yeung K, Wong M, et al. First-Line Nivolumab
 Plus Low-Dose Ipilimumab for Microsatellite Instability-High/ Mismatch RepairDeficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin
 Oncol [Internet]. 2021;40:161–70. Available from: https://doi.
- Overman MJ, Lonardi S, Yeung K, Wong M, Lenz HJ, Gelsomino F, et al. JOURNAL
 OF CLINICAL ONCOLOGY Durable Clinical Benefit With Nivolumab Plus
 Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High
 Metastatic Colorectal Cancer. J Clin Oncol [Internet]. 2018;36:773–9. Available from:
 https://doi.org/10.1200/JCO.2017.
- 575 28. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1
 576 pathways.
- 577 29. Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for
 578 cancer: An overview of FDA-approved immune checkpoint inhibitors. Vol. 62,
 579 International Immunopharmacology. Elsevier B.V.; 2018. p. 29–39.
- 30. Ghiringhelli F, Fumet JD. Is There a Place for Immunotherapy for Metastatic
 Microsatellite Stable Colorectal Cancer? Vol. 10, Frontiers in immunology. NLM
 (Medline); 2019. p. 1816.
- 583 31. Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, et al.
 584 Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in
 585 Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell. 2018 May
 586 14;33(5):853-861.e4.
- 32. Ready NE, Ott PA, Hellmann MD, Zugazagoitia J, Hann CL, de Braud F, et al.
 Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell
 Lung Cancer: Results From the CheckMate 032 Randomized Cohort. Journal of
 Thoracic Oncology. 2020 Mar 1;15(3):426–35.
- 591 33. Fan A, Wang B, Wang X, Nie Y, Fan D, Zhao X, et al. Immunotherapy in colorectal
 592 cancer: Current achievements and future perspective. Vol. 17, International Journal of
 593 Biological Sciences. Ivyspring International Publisher; 2021. p. 3837–49.
- Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, et al.
 Phase i study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clinical Cancer Research. 2015 Oct 1;21(19):4286–93.

- Shao N, Wan F, Zhu Y, Ye D. Conditional survival in patients with advanced renal cell carcinoma treated with nivolumab. Medical Science Monitor. 2019 Aug 30;25:6518–
 22.
- 36. Xu Y, Hezam K, Ali MG, Wang Y, Zhang J. The efficacy and safety of Nivolumab
 combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis. Vol. 43,
 Immunopharmacology and Immunotoxicology. Taylor and Francis Ltd.; 2021. p. 386–
 94.
- Ando K, Kishino Y, Homma T, Kusumoto S, Yamaoka T, Tanaka A, et al. Nivolumab
 plus ipilimumab versus existing immunotherapies in patients with PD-L1-positive
 advanced non-small cell lung cancer: A systematic review and network meta-analysis.
 Vol. 12, Cancers. MDPI AG; 2020. p. 1–19.
- Jiang H, Xu A, Xia W, Xia X, Li P, Zhang B, et al. Nivolumab monotherapy or
 combination therapy with ipilimumab for lung cancer: a systemic review and metaanalysis. Vol. 21, Cancer Cell International. BioMed Central Ltd; 2021.
- 612 39. O'Byrne K, Popoff E, Badin F, Lee A, Yuan Y, Lozano-Ortega G, et al. Long-term
 613 comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line
 614 therapies for advanced non-small-cell lung cancer: A systematic literature review and
 615 network meta-analysis. Lung Cancer. 2023 Mar 1;177:11–20.
- 40. Serritella A V., Shenoy NK. Nivolumab Plus Ipilimumab vs Nivolumab Alone in
 Advanced Cancers Other Than Melanoma: A Meta-Analysis. JAMA Oncol. 2023 Oct
 19;9(10):1441–6.
- 41. Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, et al. Safety
 profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Vol. 13,
 Nature Reviews Clinical Oncology. Nature Publishing Group; 2016. p. 473–86.
- 42. El Osta B, Hu F, Sadek R, Chintalapally R, Tang SC. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. Vol. 119, Critical Reviews in Oncology/Hematology.
 Elsevier Ireland Ltd; 2017. p. 1–12.
- 43. Almutairi AR, McBride A, Slack M, Erstad BL, Abraham I. Potential Immune-Related
 Adverse Events Associated With Monotherapy and Combination Therapy of
 Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic
 Review and Meta-Analysis. Vol. 10, Frontiers in Oncology. Frontiers Media S.A.; 2020.
- 630

631





Figure 1. PRISMA 2020 flow diagram



- D5: Bias due to missing data.
- D6: Bias in measurement of outcomes.
- D7: Bias in selection of the reported result.




Figure 2. (A) ROBINS-I Risk of Bias Assessment

		Risk of bias domains						
		D1	D2	D3	D4	D5	Overall	
Study	Diaz et al., 2022	+	+	+	+	+	+	
	André, et al., 2020	-	+	+	+	+	-	
	Yoshino et al., 2022	+	+	-	+	+	-	
		Domains: D1: Bias arising from the randomization process. D2: Bias due to deviations from intended intervention. D3: Bias due to missing outcome data. D4: Bias in measurement of the outcome. D5: Bias in selection of the reported result.				-	Judgement - Some concerns + Low	






Figure 2. (B) ROB-2 Risk of Bias Assessment



Heterogeneity	Statistics
---------------	------------


Tau	Tau ²	1 2	H ²	R ²	df	Q	р
0.106	0.0113 (SE= 0.0187)	64.4%	2.809		2.000	4.847	0.089

Figure 3. (A) Forest plot of ORR nivolumab intervention



Proportion


Figure 3. (B) Funnel plot of ORR nivolumab intervention



Random-Effects Model (k = 4)


medRxiv (which v	preprint doi: http was not certifie	s://doi.org/10.1101/2024 d by peer review) is the lt is made a	1.07.02.24309865; this value of the second s	ersion posted July 3 granted medRxiv a 4.0 International lic	3, 2024. The cop license to displatence .	yright holder fo ty the preprint i	r this preprint perpetuity.	CI Upper	Bound
	Interce	pt 0.534	0.0602	8.88 <	.001		0.416	C	.652
	Note. 1	au² Estimato	r: Restricted N	Maximum-l	_ikelihoo	d			
Н	leteroge	neity Statist	ics						
	Tau Tau ² I ² H ² R ² df Q							р	
	0.106	0.0113 (SE	= 0.0118)	79.22%	4.81	1.	3.000	12.727	0.005

Figure 4. (A) Forest plot of ORR Nivolumab and Ipilimum



Proportion


Figure 4. (B) Funnel plot of ORR Nivolumab and Ipilimum



Random-Effects Model (k = 6)


v preprint doi: http was not certifie	os://doi.org/10.1101/2024.07.02 d by peer ceview) is the autho It is made availab	2.24309865; this v or/funder, who has ble under a CC-BY	version posted July 3 s granted medRxiv a 7 4.0 International lice	, 2024. The copyrigh license to display the ense .	t holder for t	perpetuity d	CI Upper	Bound
Intercept	t 0.336	0.0747	4.50 <.001		0.189		(0.482
			•					
Note. Ta	u ² Estimator: Re	stricted N	laximum-Li	kelihood				
	u ² Estimator: Re neity Statistics	estricted N	1aximum-Li	kelihood				
		estricted N	1aximum-Li I ²	kelihood H²	R ²	df	Q	р

Figure 5. (A) Forest plot of ORR Pembrolizumab intervent



Proportion

Figure 5. (B) Funnel plot of ORR Pembrolizumab interver



Random-Effects Model (k = 3)

medRxiv preprint d (whic <u>h was not c</u>	dRxiv preprint doi: https://doi.costumiate.or.or.or.or.or.or.or.or.or.or.or.or.or.											
Interd		is made availat	0.0807	4.0 Internatio 8.40	nal license .		0	.520	0.836			
interv	opt o											
		•		·				•				
Note	Tau ² Estim	nator: Re	stricted N	laximur	n-Likeli	hood						
Hetero	geneity S	tatistics										
Tau	Tau Tau ² I ² H ² R ² df Q p											
0.113	3 0.012	7 (SE= (0.0198)	66.2	6%	2.964		2.000	5.848	0.054		

Figure 6. (A) Forest plot of OS Nivolumab intervention




Figure 6. (B) Funnel plot of OS Nivolumab intervention






Figure 7. (A) Forest plot of OS Nivolumab and Ipilimumal



Proportion


Figure 7. (B) Funnel plot of OS nivolumab and Ipilimuma



Random-Effects Model (k = 5)


was not certifie	ed by preserview) is the a It is made av	author/funder, who h ailable under a CC-I	s version posted July as granted medRxiv BY 4.0 international I	a license to display icense .		t in Berpetuity	CI Upper	Boun
Intercept	0.562	0.0958	5.86 <	.001	0.374		C	0.749
Note Ta	u² Estimator: F	Restricted M	/aximum-l	ikelihood				
	u ² Estimator: F neity Statistics		Maximum-L	ikelihood				
		8	Maximum-L	ikelihood H²	R ²	df	Q	р

Figure 8. (A) Forest plot of OS Pembrolizumab intervention




Proportion

Figure 8. (B) Funnel plot of OS Pembrolizumab interventi




	Lotinate	30	-			Dound	or opp	er bound
(which was not certific Intercep	tps://doi.org/10.1101/2024.07.02 ed by peer review) is the autho (t is made availab)	/funder, who has	granted medRxiv a l	icense to display	the preprint in	perpetuity. 0.427		0.639
	au² Estimator: Re	stricted N	1aximum-Li	kelihood				
Heteroge	eneity Statistics							
Tau	Tau ²		1 2	H ²	R ²	df	Q	р
0.046	0.0021 (SE= 0	.0091)	22.35%	1.288		2.000	2.626	0.269

Figure 9. (A) Forest plot of PFS Nivolumab intervention




Proportion

Figure 9. (B) Funnel plot of PFS Nivolumab intervention




Rxiv preprint doi: http ich was not certifie	s://doi.org/40, 1104/2024.07.02. d by peer review) is the author/ It is made available	24309265; this ver /funder, who has g e under a CC-BY 4	sion posted July ranted medRxiv .0 International I	3, 2024. The cop a license to displace	by right holder for th ay the preprint in pe	is preprint d erpetaity.	CI Upper	Bound			
Intercept								0.670		0.766	
	•	•	•								
Note. Ta	u² Estimator: Re	stricted M	aximum-	Likelihoo	d						
Heteroge	neity Statistics										
Tau	Tau ²	2	H ²	R ²	df	Q	р				

Figure 10. (A) Forest plot of OS Nivolumab and Ipilimuma



Proportion

Figure 10. (B) Funnel plot of OS Nivolumab and Ipilimum



Random-Effects Model (k = 5)

medRxiv preprint doi (which was not cer	https://doi.org/001101/202 ified by peer review) is the	07.02.2430965; this e author/funder, who ha available under a CC-E	s version posted Jul as granted medRxiv	y 3, 2024. The copyrig a license to display t	ph t holder fo he preprint i	n perpetuity.	CI Upp	er Bound		
Interc				<.001		0.343		0.725		
Note.	Tau ² Estimator	: Restricted	Maximum	-Likelihood						
Hetero	geneity Statist	ics								
Tau	Tau Tau ² l ² H ² R ² df Q p									
0.207	0.043 (SE	0.0005.)	95.77%	23.634		4.000	63.889	<.001		

Figure 11. (A) Forest plot of PFS Pembrolizumab interven




Figure 11. (B) Funnel plot of PFS Pembrolizumab interve